Business
-
Several months after acquiring the rights to TNX-1900 oxytocin nasal spray for the treatment of migraine headaches from Trigemina, Tonix Pharmaceuticals announced that it has acquired an exclusive license to technology from the University of… Read more . . .
-
Hikma Pharmaceuticals announced that the FDA has approved 100 mcg/50 mcg and 250 mcg/50 mcg doses of the company’s fluticasone propionate / salmeterol DPI (VR315), a generic version of Advair Diskus and that the company… Read more . . .
-
According to Opiant Pharmaceuticals, the US Biomedical Advanced Research and Development Authority (BARDA) is providing an additional $3.5 million for development of Opiant’s OPNT003 nalmefene nasal spray for the treatment of opioid overdose. BARDA had previously provided $4.6… Read more . . .
-
The US Department of Defense is providing $8.5 million to fund development of a Q-Griffithsin (Q-GRFT) nasal spray at the University of Louisville, the university said. The funding will support the PREVENT-CoV project for development… Read more . . .
-
Cyrano Therapeutics announced that it has raised $12.8 million in Series A financing to allow it to complete a Phase 2 trial of its CYR-064 intranasal theophylline for the restoration of the senses of smell… Read more . . .
-
Savara Pharmaceuticals has announced that it is halting development of its AeroVanc vancomycin DPI after the Phase 3 AVAIL trial of AeroVanc for the treatment of MRSA lung infections in cystic fibrosis patients failed to… Read more . . .
-
Kindeva Drug Delivery has announced a new agreement with Israeli medical cannabis company Breath of Life International (BOL Pharma) for development of formulations of several cannabinoids for delivery via Kindeva MDIs. The formulations will initially… Read more . . .
-
US-based startup Kinaset Therapeutics has signed a licensing and develop an inhaled pan-JAK inhibitor that was in Vectura’s pipeline prior to that company’s transformation into an inhalation CDMO. In July 2019, Vectura announced that it… Read more . . .
-
Dr. Reddy’s Laboratories said that it has acquired several mometasone and mometasone/azelastine nasal sprays for the treatment of seasonal and perennial allergic rhinitis from Glenmark for Russia, Kazakhstan, Uzbekistan, and Ukraine. The brands included in… Read more . . .
-
Verona Pharma announced that it has secured up to $30 million in debt financing facility from Silicon Valley Bank for pre-commercialization activities related to the company’s nebulized ensifentrine, which is in Phase 3 development for… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland